Elafibranor(GFT505)
- ₹0
- Product name: Elafibranor(GFT505)
- CAS: 923978-27-2
- MF: C22H24O4S
- MW: 384.49
- EINECS:-0
- MDL Number:
- Synonyms:Elafibranor(GFT505);elafibranor E;Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-[4-(methylthio)phenyl]-3-oxo-1-propen-1-yl]phenoxy]-2-methyl-;2-[2,6-Dimethyl-4-[(1E)-3-[4-(methylthio)phenyl]-3-oxo-1-propen-1-yl]phenoxy]-2-methylpropanoic acid;(E)-2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxoprop-1-en-1-yl)phenoxy)-2-methylpropanoic acid;SureCN815512;Elafibranor (GFT-505, Ph III);GFT505(ELAFIBRANOR)
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|
Properties
Boiling point :569.0±50.0 °C(Predicted)
Density :1.21±0.1 g/cm3(Predicted)
storage temp. :-20°
solubility :Soluble in DMSO (up to at least 25 mg/ml).
form :solid
pka :3.30±0.11(Predicted)
color :Pale yellow
Stability :Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month.
Density :1.21±0.1 g/cm3(Predicted)
storage temp. :-20°
solubility :Soluble in DMSO (up to at least 25 mg/ml).
form :solid
pka :3.30±0.11(Predicted)
color :Pale yellow
Stability :Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month.
Safety Information
Symbol(GHS): | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
Precautionary statements: |
|
Description
Elafibranor is an agonist of the peroxisome proliferator-activated receptors (PPAR) α and δ. It increases HDL secretion and expression of the lipid-related genes ABCA1, PLIN2, and ABHD5 in Caco-2/TC7 cells in a PPARα-dependent manner. Elafibranor (10 mg/kg) decreases levels of plasma triglycerides and total cholesterol while increasing plasma HDL and expression of Acox1, a PPARα target gene, in the liver of ApoE2-KI wild-type, but not PPARα knockout, mice fed a Western diet. However, PPARα knockout mice exhibit a decrease in plasma total and non-HDL cholesterol levels, indicating PPARδ has a role in these functions. Elafibranor (30 mg/kg) reduces diet-induced macro- and micro-steatosis in a PPARα-deficient mouse model of non-alcoholic steatohepatitis. It also reduces cholesterol and triglyceride accumulation as well as macrovesicular steatosis in the liver of insulin-resistant db/db mice fed the methionine-choline deficient (MCD) diet. Formulations containing elafibranor are under clinical investigation for the treatment of non-alcoholic steatohepatitis.Related product price
- METHOPRENE ACID
₹35235.38